Context Therapeutics (NASDAQ:CNTX) Earns “Buy” Rating from D. Boral Capital

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $9.00 price target on the stock.

CNTX has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Trading Down 6.0 %

Shares of NASDAQ CNTX opened at $0.77 on Friday. The firm’s 50-day moving average price is $0.86 and its 200-day moving average price is $1.45. The stock has a market capitalization of $57.76 million, a price-to-earnings ratio of -0.85 and a beta of 2.06. Context Therapeutics has a 12-month low of $0.64 and a 12-month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. On average, equities analysts predict that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors have recently bought and sold shares of CNTX. Jane Street Group LLC acquired a new stake in Context Therapeutics in the fourth quarter valued at approximately $29,000. Citadel Advisors LLC acquired a new stake in Context Therapeutics in the fourth quarter valued at approximately $31,000. Shay Capital LLC acquired a new stake in Context Therapeutics in the fourth quarter valued at approximately $52,000. Clear Harbor Asset Management LLC boosted its stake in Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after acquiring an additional 21,804 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Context Therapeutics in the third quarter valued at approximately $89,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.